Alector
IPOBreakthroughs come from unexpected places.
Public · South San Francisco, United States · Founded 2013 · $162.5M raised
- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- alector.com
- Total Funding
- $162.5M
- Last Round
- $133.0M Series EJul 2018
- Rounds
- 2
- Type
- Public
About
Alector develops therapies to treat neurodegenerative diseases by combining advanced science and technology with expertise in human genetics, neuroscience, and immunology. Their pipeline targets toxic proteins, deficient proteins, and immune/nerve cell function to improve brain health and patient outcomes.
Summary
Alector is a Biotech company based in South San Francisco, United States, founded in 2013. It has raised $162.5M in total across 2 rounds, most recently a $133.0M Series E round in Jul 2018. Investors include Hercules Capital, AbbVie Ventures and Amgen.
Tech & App Stack
6 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2025
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...